ES2749927T3 - Derivado de anfotericina b con toxicidad reducida - Google Patents

Derivado de anfotericina b con toxicidad reducida Download PDF

Info

Publication number
ES2749927T3
ES2749927T3 ES15793421T ES15793421T ES2749927T3 ES 2749927 T3 ES2749927 T3 ES 2749927T3 ES 15793421 T ES15793421 T ES 15793421T ES 15793421 T ES15793421 T ES 15793421T ES 2749927 T3 ES2749927 T3 ES 2749927T3
Authority
ES
Spain
Prior art keywords
epiamb
amb
mmol
administration
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15793421T
Other languages
English (en)
Spanish (es)
Inventor
Martin Burke
Brice Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Application granted granted Critical
Publication of ES2749927T3 publication Critical patent/ES2749927T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES15793421T 2014-05-16 2015-05-15 Derivado de anfotericina b con toxicidad reducida Active ES2749927T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461994450P 2014-05-16 2014-05-16
US201462045907P 2014-09-04 2014-09-04
PCT/US2015/030965 WO2015175875A1 (en) 2014-05-16 2015-05-15 Amphotericin b derivative with reduced toxicity

Publications (1)

Publication Number Publication Date
ES2749927T3 true ES2749927T3 (es) 2020-03-24

Family

ID=54480735

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15793421T Active ES2749927T3 (es) 2014-05-16 2015-05-15 Derivado de anfotericina b con toxicidad reducida

Country Status (7)

Country Link
US (1) US9738677B2 (enExample)
EP (1) EP3142672B1 (enExample)
JP (1) JP6543272B2 (enExample)
CA (1) CA2981288C (enExample)
DK (1) DK3142672T3 (enExample)
ES (1) ES2749927T3 (enExample)
WO (1) WO2015175875A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6755859B2 (ja) * 2014-10-17 2020-09-16 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ アムホテリシンｂの毒性が低減された誘導体の規模変更可能な合成法
US9957290B2 (en) 2015-04-15 2018-05-01 Sfunga Therapeutics, Inc. Derivatives of amphotericin B
KR102893040B1 (ko) 2018-09-07 2025-11-27 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 독성이 감소된 혼성 암포테리신 b 유도체
AU2020325054A1 (en) * 2019-08-08 2022-03-03 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity
EP4009968A4 (en) * 2019-08-09 2023-08-16 The Board Of Trustees Of The University Of Illinois Combination treatment of systemic fungal infections
WO2022035752A1 (en) * 2020-08-10 2022-02-17 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin b
CA3261962A1 (en) * 2022-07-08 2024-01-11 The Board Of Trustees Of The University Of Illinois TRANSFER OF C2 EPIMERIZED SUGARS TO AGLYCONIC AMPHOTEROCIBN B

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641480A1 (en) * 2003-05-27 2006-04-05 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
JP2008503586A (ja) * 2004-06-21 2008-02-07 ネクター セラピューティクス アンフォテリシンｂを含む組成物、方法、およびシステム
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2014059436A1 (en) * 2012-10-12 2014-04-17 The Board Of Trustees Of The University Of Illinois Electronic tuning of site selectivity
JP6755859B2 (ja) * 2014-10-17 2020-09-16 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ アムホテリシンｂの毒性が低減された誘導体の規模変更可能な合成法

Also Published As

Publication number Publication date
US20170088572A1 (en) 2017-03-30
WO2015175875A1 (en) 2015-11-19
EP3142672B1 (en) 2019-09-25
JP2017518982A (ja) 2017-07-13
EP3142672A1 (en) 2017-03-22
CA2981288C (en) 2022-12-06
CA2981288A1 (en) 2015-11-19
US9738677B2 (en) 2017-08-22
JP6543272B2 (ja) 2019-07-10
EP3142672A4 (en) 2017-11-15
DK3142672T3 (da) 2019-10-21

Similar Documents

Publication Publication Date Title
ES2749927T3 (es) Derivado de anfotericina b con toxicidad reducida
ES2963759T3 (es) Moduladores de la 5'-nucleotidasa, ecto y su uso
ES2565083T3 (es) Biodefensas usando macrólidos que contienen triazol
US20210353623A1 (en) Therapeutic agents and methods
WO2014165676A1 (en) Amphotericin b derivative with reduced toxicity
ES2682328T3 (es) Derivados de la anfotericina B con índice terapéutico mejorado
Nosanchuk Current status and future of antifungal therapy for systemic mycoses
US20160136121A1 (en) Use of cilastatin to reduce the nephrotoxicity of different compounds
CA2876074A1 (en) N-substituted second generation derivatives of antifungal antibiotic amphotericin b and methods of their preparation and application
ES2535327T3 (es) Derivados de rifamicina
ES2727686T3 (es) Tratamiento de enfermedades que implican mucina
CN104368011B (zh) 一种药物甜菜碱缀合物、其药物组合物及应用
US20220298203A1 (en) Therapeutic agents and methods
US10683318B2 (en) Scalable synthesis of reduced toxicity derivative of amphotericin B
WO2016014779A1 (en) Antifungal polyene macrolide derivatives with reduced mammalian toxicity
US20070078111A1 (en) LPA2 receptor agonist inhibitors of CFTR
US20220008376A1 (en) Inhibitors of type 3 secretion system and antibiotic therapy
US20140315838A1 (en) Methods of Treating Recurring Bacterial Infection
CN101259134A (zh) 松果菊苷的制药新用途
CN100387235C (zh) 松果菊苷的制药新用途
Endo Synthesis-enabled understanding of the mechanism of action of amphotericin B and the development of increased therapeutic derivatives
Li et al. γ-mangostin from Garcinia mangostana (L.) exerts the antifungal activity against Cryptococcus neoformans by inhibiting ribosome biogenesis
Masoudi Characterisation and formulation of natural cyclodecapeptides with anti-Candida activity
Dietrick In Silico and In Vitro Drug Discovery Strategies and the Chemical Investigation of Endophytic Fungi
ES2998053T3 (en) Linear lipopeptide paenipeptins and methods of using the same